NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price, Price Target & More

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) issued its earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.16) by $0.01. The biopharmaceutical company earned $8.59 million during the quarter, compared to the consensus estimate of $11.18 million. Synergy Pharmaceuticals had a negative return on equity of 652.66% and a negative net margin of 773.82%. The firm's revenue for the quarter was up 776.5% on a year-over-year basis. During the same period in the previous year, the company posted ($0.30) earnings per share. View Synergy Pharmaceuticals' Earnings History.

8 analysts have issued 12-month price targets for Synergy Pharmaceuticals' shares. Their predictions range from $2.50 to $15.00. On average, they expect Synergy Pharmaceuticals' share price to reach $8.8125 in the next year. This suggests a possible upside of 363.8% from the stock's current price. View Analyst Ratings for Synergy Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synergy Pharmaceuticals in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Synergy Pharmaceuticals saw a drop in short interest in June. As of June 29th, there was short interest totalling 54,868,105 shares, a drop of 12.8% from the June 15th total of 62,939,216 shares. Based on an average trading volume of 3,251,186 shares, the short-interest ratio is currently 16.9 days. Currently, 22.3% of the shares of the company are sold short. View Synergy Pharmaceuticals' Current Options Chain.

Some companies that are related to Synergy Pharmaceuticals include PTC Therapeutics (PTCT), Cambrex (CBM), Mallinckrodt (MNK), AnaptysBio (ANAB), Aimmune Therapeutics (AIMT), Mirati Therapeutics (MRTX), G1 Therapeutics (GTHX), IMMURON Ltd/S (IMRN), ARMO Biosciences (ARMO), Pacira Pharmaceuticals (PCRX), Corcept Therapeutics (CORT), Innoviva (INVA), Biohaven Pharmaceutical (BHVN), TherapeuticsMD (TXMD) and Theravance Biopharma (TBPH).

Media headlines about SGYP stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Synergy Pharmaceuticals earned a news impact score of 0.24 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 46.73 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SGYP stock can currently be purchased for approximately $1.90.

Synergy Pharmaceuticals has a market capitalization of $468.81 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]